Opco lists five potential biotech targets into JPMorgan conference

Oppenheimer laid out five “aspirational” potential takeover targets in biotech heading into the annual JPMorgan Health Care Conference. “We need more M&A, and not the garden variety we’ve gotten since COVID,” the analyst tells investors in a research note. The firm believes a takeout or two “could catalyze a reversal” of the SPDR S&P Biotech (XBI). Oppenheimer says each of its potential targets are “large enough to make headlines.” The firm lists Blueprint Medicines (BPMC), Janux Therapeutics (JANX), Arcellx (ACLX), Nuvalent (NUVL), and Viking Therapeutics (VKTX) as possible takeout targets in biotechnology.